Background And Objectives: The decision to initiate pharmacotherapy for alcohol withdrawal is typically based on examining self-reported use of alcohol and symptoms of withdrawal. Phosphatidylethanol (PEth) is a biomarker that could aim in clinical decision-making in withdrawal management.
Methods: This report describes three cases highlighting the potential clinical utility of PEth in caring for individuals at risk for alcohol withdrawal.
Results: Two of the cases received phenobarbital when their PEth showed that the risk of withdrawal was low and one case where PEth could have shown this was needed. The results were only available in a delayed fashion, however, could have been useful in informing clinical care.
Discussion And Conclusion: PEth can be a useful tool if available without delay. PEth can be used to quickly rule out alcohol withdrawal and avoid misdiagnoses and prolonged hospital stays.
Scientific Significance: This is a clinical case study available looking at PEth and withdrawal in hospitalized patients. It proposes that PEth can be used as a way to quickly rule out alcohol withdrawal to avoid misdiagnoses and the possibility of a prolonged hospital stay.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11032224 | PMC |
| http://dx.doi.org/10.1111/ajad.13516 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Is there a risk of esketamine misuse in clinical practice?
Ther Adv Drug Saf
January 2025
Pharmacology Department, School of Medicine, University of Valladolid, Valladolid, Spain.
In 2019, intranasal esketamine gained approval as a promising therapy for those individuals grappling with treatment-resistant depression. Both clinical trials and real-world studies have underscored its efficacy in alleviating and remitting depressive symptoms, with sustained benefits observed for nearly 4.5 years.
View Article and Find Full Text PDFAssociation Between GABRG2 and Self-Rating of the Effects of Alcohol in a French Young Adult Sample.
Risk Manag Healthc Policy
January 2025
Université Paris Cité, Inserm U1266, Institut de Psychiatrie et Neurosciences de Paris (IPNP), Team Vulnerability of Psychiatric and Addictive Disorders, Paris, France.
Purpose: Alcohol use is a leading risk factor for preventable death, injury, and disease globally. Low sensitivity to the effects of alcohol is influenced by genes and predicts risk for harmful alcohol use and alcohol use disorder (AUD). Alcohol induces effects partly by modulation of gamma-aminobutyric acid receptors type A (GABARs).
View Article and Find Full Text PDFEvaluation of Lyso-Gb1 as a biomarker for Gaucher disease treatment outcomes using data from the Gaucher Outcome Survey.
Orphanet J Rare Dis
January 2025
Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital, Heinrich- Heine University, Düsseldorf, Germany.
Background: Patients with Gaucher disease (GD) require continual monitoring; however, lack of specific disease biomarkers was a significant challenge in the past. Glucosylsphingosine (lyso-Gb1) has been shown to be a reliable, key, specific, and sensitive biomarker for diagnosis, prognosis, and treatment response in clinical studies of patients with GD. We evaluated the change in lyso-Gb1 concentration over time following enzyme replacement therapy in patients with confirmed GD using real-world data from the Gaucher Outcome Survey disease registry.
View Article and Find Full Text PDFWhispering-gallery-mode (WGM) microresonators are typically studied for surface (bio)chemical sensing, mainly relying on small refractive index changes occurring within a nanometer range from their walls surface. This high sensitivity, reaching up to 10 refractive index unit (RIU, ∼2.5 nm/RIU and measured at a femtometer resolution) leads to broad ranges of applications, especially for biosensing purposes through the monitoring of molecular binding events.
View Article and Find Full Text PDFCorrelates of length of stay in a short-term inpatient residential addiction treatment facility.
Alcohol Clin Exp Res (Hoboken)
January 2025
Institute of Behavioral Science, Feinstein Institutes for Medical Research, Manhasset, New York, USA.
Background: There is a gap in the extant literature regarding length of stay (LOS) in short-term inpatient addiction treatment facilities. Furthermore, there is a lack in focus on treatment factors which may be better indicators for positive patient outcomes than demographic profiles. The current study sought to examine modifiable correlates of LOS within a short-term inpatient residential facility to extend LOS and improve patient outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!